Eli Lilly invested in Abridge as the health tech startup expands into clinical trial recruitment and broadens its reach across life sciences. The investment, made through Lilly’s venture arm, is meant to accelerate Abridge’s operations in connecting sites, investigators, and patients to studies while strengthening Lilly’s exposure to workflow and enrollment tools. The move reflects a continued shift from AI documentation toward AI-enabled execution in trials—where enrollment speed can directly influence program timelines and costs. For Lilly, investing in recruitment tooling aligns with the company’s broader digitization push across clinical development.